The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Toxicities Associated With PI3K Inhibitors

Denise A. Yardley, MD
Published Online: 1:52 AM, Fri December 12, 2014
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.

<<< Go back to the SABCS conference page



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.